

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **SUPPLEMENTAL ANNOUNCEMENT**

#### **THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023**

Reference is made to the annual report of The United Laboratories international Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2023 (the “**2023 Annual Report**”) published on 29 April 2024. Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meaning as those defined in the 2023 Annual Report.

The Company would like to supplement the following information in relation of the share award scheme adopted on 26 October 2023 (the “**Share Award Scheme**”) by the Company and the awarded shares granted under the Share Award Scheme on 13 November 2023.

The Share Award Scheme is to reward the directors and employees of the Group for their hard work, contribution and loyalty and align their interest with those of the shareholders of the Company. The number of shares to be funded by issue of new shares of the Company and/or purchased of existing shares on-market which may be awarded under the Share Award Scheme shall not exceed 10% of the issued shares of the Company as at 26 October 2023 (i.e. 181,702,650 shares). The principal terms of the Share Award Scheme are set out in the Company’s circular dated 15 September 2023.

On 13 November 2023, the directors of the Company resolved to grant a total of 12,096,900 shares (the “**Awarded Shares**”) to selected participants in accordance with the terms of the Share Award Scheme. All of the 12,096,900 Awarded Shares are granted by way of acquisition of the existing shares of the Company through on-market transactions by the trustee of the Share Award Scheme. The grant of 12,096,900 Awarded Shares will not result in any issue of new shares of the Company. Details of the grant of the Awarded Shares are disclosed in the Company’s announcement dated 13 November 2023.

During the year ended 31 December 2023, the movements of the unvested Awarded Shares granted under the Share Award Scheme are as follows:

Grantee name /categories	Date of grant	Vesting period	Number of unvested Awarded Shares					As at 31 Dec 2023
			As at 1 Jan 2023	Granted during the year	Vested during the year	Lapsed during the year	Cancelled during the year	
<b>Directors of the Company:</b>								
Tsoi Hoi Shan	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	575,100	-	-	-	575,100
Leung Wing Hon	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	401,100	-	-	-	401,100
Choy Siu Chit	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	268,800	-	-	-	268,800
Fang Yu Ping	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	186,900	-	-	-	186,900
Zou Xian Hong	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	186,900	-	-	-	186,900
Zhu Su Yan	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	186,900	-	-	-	186,900
<b>Other employees of the Group:</b>	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	10,291,200	-	-	-	10,291,200
<b>Total Awarded Shares granted:</b>	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	12,096,900	-	-	-	12,096,900
<b>Five highest paid individuals in aggregate (Note 1):</b>	13 Nov 2023	13 Nov 2024 to 13 Nov 2026	-	1,618,800	-	-	-	1,618,800

Notes:

1. All of the five highest paid individuals of the Group are directors of the Company.
2. There is no purchase price to be paid by the grantees. The consideration for each grant of the Awarded Shares is nil.
3. The closing prices of the shares of the Company immediate before the date of the grant and on the date of the grant of the Awarded Shares were HK\$7.77 and HK\$7.45 per share respectively.
4. The fair value of the unvested Awarded Shares granted was HK\$7.45 per share as at the date of grant.
5. No Awarded Shares were purchased by the trustee of the Share Award Scheme during the year ended 31 December 2023.
6. The accounting standard and policy adopted are set out in note 3 to the consolidated financial statements in 2023 Annual Report.

The total number of shares available for issue under the Share Award Scheme is 169,605,750 shares, representing 9.33% of the issued shares of the Company as at the date of the 2023 Annual Report.

The above supplemental information does not affect other information contained in the 2023 Annual Report. All other information in the 2023 Annual Report remains correct and unchanged.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
Tsoi Hoi Shan  
*Chairman*

Hong Kong, 25 September 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.